What is tesofensine, and does it work for weight loss?

The short answer

Tesofensine is a triple monoamine reuptake inhibitor — a small-molecule drug, not a peptide — that blocks reuptake of noradrenaline, dopamine, and serotonin to suppress appetite. In a Phase 2 trial it produced about 10% weight loss, but dose-dependent rises in heart rate and blood pressure stalled its development. It is not approved.

Evidence tier: Tier 1 for the Phase 2 weight-loss data; Tier 2 for mechanism and safety context. Educational content, not medical advice.

The key points:

• Not a peptide — tesofensine is a synthetic small molecule (a triple monoamine reuptake inhibitor)
• ~10% weight loss at 0.5 mg over 24 weeks in a Phase 2 trial
• Cardiovascular signal — dose-dependent increases in heart rate and blood pressure
• Not approved — development for obesity stalled; no Phase 3 approval

For approved appetite-based options, see the GLP-1 complete guide.

What is tesofensine, and is it a peptide?

Evidence tier: 2 — established pharmacology.

Tesofensine (development code NS2330) is a synthetic small-molecule drug, not a peptide — a distinction worth stating plainly because it's often lumped in with research peptides in weight-loss forums. Chemically it's a triple monoamine reuptake inhibitor: it blocks the presynaptic reuptake of noradrenaline, dopamine, and serotonin, raising the synaptic levels of all three neurotransmitters (tesofensine review, PMID 19777399). That mechanism is completely different from the GLP-1 and amylin analogs that dominate modern obesity pharmacology, which are peptides that act on gut-hormone satiety pathways.

Tesofensine was originally developed for Alzheimer's and Parkinson's disease, where it disappointed on cognitive endpoints. But trial participants consistently lost weight, which redirected the compound toward obesity. So its appetite effect is, in a sense, a repurposed side effect: the same monoamine boost that was meant to help cognition turned out to blunt hunger. Preclinical work suggests the appetite suppression is driven largely by indirect stimulation of alpha-1 adrenoceptor and dopamine D1 pathways rather than serotonin alone (Axel et al. 2010, PMID 20200509). Understanding that it's a centrally-acting stimulant-like drug — not a gut peptide — is the key to understanding both why it works and why it raised safety concerns.

How much weight loss did tesofensine produce?

Evidence tier: 1 — Phase 2 randomized controlled trial.

The headline evidence is the TIPO-1 trial — a 24-week, Phase 2, randomized, double-blind, placebo-controlled study in 203 obese patients across five Danish centers, published in The Lancet (Astrup et al. 2008, PMID 18950853; registered as NCT00394667). After an energy-restricted diet run-in, participants were randomized to tesofensine 0.25 mg, 0.5 mg, or 1.0 mg, or placebo, once daily. Diet plus placebo produced about 2% weight loss; tesofensine produced 4.5%, 9.2%, and 10.6% at the three ascending doses.

That ~9–11% figure at the middle-to-high doses is genuinely large for a monotherapy — roughly double what the era's approved anti-obesity drugs delivered, which is exactly why the result generated so much excitement. The appetite mechanism is consistent with the numbers: a companion analysis found tesofensine meaningfully reduced hunger and increased fullness ratings (appetite-sensation study, PMID 21720440). The honest caveat is that this is a single Phase 2 trial of 24 weeks — proof of a strong short-term effect, not confirmation of durable, safe long-term weight loss. And that middle 0.5 mg dose, which the developers highlighted as the best efficacy-tolerability balance, is where the story turns to safety.

Why did tesofensine's development stall?

Evidence tier: 2 — safety-signal interpretation.

The problem was cardiovascular. As a stimulant-like triple reuptake inhibitor, tesofensine raised sympathetic tone. In TIPO-1, the 0.5 mg dose increased heart rate by about 7.4 beats per minute versus placebo, and the highest 1.0 mg dose was associated with significant increases in blood pressure (Astrup et al. 2008, PMID 18950853). For a drug intended for chronic use in a population already at elevated cardiometabolic risk, a sustained rise in heart rate and blood pressure is a serious liability — it's the same class of concern that led regulators to pull sibutramine (another appetite drug that raised heart rate and blood pressure) from the market.

Preclinical work tried to rescue the profile: in rats, adding an anti-hypertensive agent preserved tesofensine's appetite suppression while blunting its cardiovascular effects (Bentzen et al. 2013, PMID 23784901), suggesting the weight loss and the blood-pressure rise are at least partly separable. But that's a rat study, not a human program. On the trial-integrity side, it's also worth noting that The Lancet later issued an expression of concern about the 2008 paper — an unresolved flag that further complicates how much weight to place on the original data. The combination of a real cardiovascular signal, YMYL-grade regulatory caution, and a shifting competitive landscape (GLP-1 drugs arriving with strong efficacy and cardiovascular benefit rather than harm) is why tesofensine never completed a successful path to approval for obesity in major markets.

How does tesofensine compare to modern weight-loss drugs?

Evidence tier: 2 — cross-trial and mechanistic context.

Tesofensine's ~10% Phase 2 result looks competitive next to first-generation obesity drugs, but the field has moved decisively toward gut-hormone peptides. Semaglutide and tirzepatide — GLP-1 and GLP-1/GIP agonists — deliver comparable or larger weight loss with a fundamentally more favorable cardiovascular story: semaglutide actually reduced major cardiovascular events in a dedicated outcomes trial, the opposite of tesofensine's heart-rate-and-blood-pressure liability. That contrast matters enormously for a chronic-use obesity drug and is central to why development priorities shifted. For the modern landscape, see the next-gen multi-agonists overview.

Comparing tesofensine's single 24-week Phase 2 to multi-thousand-patient GLP-1 outcome trials is cross-trial, not head-to-head, so treat any direct ranking cautiously. The fair summary: tesofensine demonstrated that central monoamine modulation can drive real weight loss, but it belongs to an older, riskier pharmacological approach that appetite-hormone peptides have largely superseded. A stimulant that raises heart rate is a hard sell when a peptide can match the weight loss and lower cardiovascular risk instead. Some clinics in a few countries (notably reports from Mexico) have marketed compounded tesofensine, but that is not the same as approval by the FDA or EMA, and it carries the safety questions the trials never resolved.

Should you try to source tesofensine?

Evidence tier: 2 — safety and sourcing.

No — sourcing tesofensine for self-directed weight loss is not a good idea. It is not an FDA- or EMA-approved obesity drug, its best human data come from a single flagged Phase 2 trial, and its defining safety problem is a dose-dependent rise in heart rate and blood pressure that requires medical monitoring you cannot do safely on your own. Anything sold online as "tesofensine" is a gray-market, unverified product with the usual authenticity, purity, and dosing risks — and unlike an inert supplement, this is a centrally-acting cardiovascular-active drug where getting the dose wrong has real consequences (spotting counterfeit and gray-market products).

If your actual goal is meaningful weight loss, the evidence-based path is the approved appetite-hormone therapies used under medical supervision, plus the fundamentals — not an abandoned stimulant. Tesofensine is best understood as an instructive cautionary tale: a compound with a striking efficacy signal that nonetheless failed to reach patients because the safety trade-off didn't hold up against safer alternatives. That's a recurring pattern in obesity pharmacology, and it's why "big weight-loss number in one trial" is never sufficient on its own.

Limitations

This is educational content, not medical advice.

• Human evidence is one Phase 2 trial (TIPO-1, 24 weeks) — and The Lancet issued an expression of concern about it.
• Cardiovascular safety is the core unresolved problem — dose-dependent heart-rate and blood-pressure increases.
• Not approved by the FDA or EMA as an obesity drug; no successful Phase 3 program.
• Not a peptide — it's a centrally-acting small-molecule stimulant, a different risk class from gut-hormone therapies.
• Cross-trial comparisons aren't head-to-head — don't directly rank it against GLP-1 outcome-trial data.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Tesofensine is a triple monoamine reuptake inhibitor — a small-molecule stimulant, not a peptide — that produced roughly 10% weight loss at 0.5 mg over 24 weeks in the Phase 2 TIPO-1 trial. That efficacy signal was strong enough to draw serious attention, but the same sympathetic mechanism that suppresses appetite also raised heart rate and, at higher doses, blood pressure. For a drug meant for chronic use in people already at cardiometabolic risk, that trade-off proved hard to justify — especially as GLP-1 peptides arrived offering similar weight loss with cardiovascular benefit rather than harm. Tesofensine never gained approval for obesity in major markets, its one pivotal paper carries an editorial expression of concern, and gray-market versions are unverified and genuinely risky. Treat it as a cautionary lesson, not a shortcut.

Related on this site

• GLP-1 complete guide
• Next-gen multi-agonists overview
• Cagrilintide (amylin analog) explained
• AOD-9604 fat-loss reality check
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. 2008. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372(9653):1906–1913. PMID 18950853 — the pivotal TIPO-1 Phase 2 efficacy and safety trial.
• Doggrell SA. 2009. Tesofensine — a novel potent weight loss medicine (review). PMID 19777399 — mechanism and monoamine-reuptake pharmacology.
• Axel AM, et al. 2010. Tesofensine induces appetite suppression via alpha-1 adrenoceptor and dopamine D1 pathways in diet-induced obese rats. PMID 20200509 — preclinical mechanism.
• Bentzen BH, et al. 2013. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity. PMID 23784901 — cardiovascular safety signal.
• Sjödin A, et al. 2011. The effect of tesofensine on appetite sensations. PMID 21720440 — hunger/fullness mechanism.
• TIPO-1 trial registration. NCT00394667 — ClinicalTrials.gov record.